Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Clinical trial NCT01712945 · TERMINATED
Trial details
- NCT number
- NCT01712945
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-01
- Primary completion
- 2017-08-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.